Generics Industry News Search
 |
|
|
|
|
|
|
June 2012 News Archive |
|
|
| |
|
Pfizer's patent on Viagra active ingredient Sildenafil expired on May 17, since when six local companies, including CJ Cheiljedang and Hanmi Pharm, have released prescription-only generic versions...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Pharma major, Lupin, announced today that its subsidiary, Lupin Pharmaceuticals has received approval for Suprax (Cefixime) capsules...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Merck sued the Sandoz unit of Swiss drugmaker Novartis and Intas Pharmaceuticals to block them from selling generic forms of Emend...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Perrigo today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Calcium acetate capsules, the generic equivalent of Phoslo gelcaps...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Mylan today announced that its UK and Italy-based subsidiaries have launched Lamivudine film coated tablets...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Mylan today announced that its Canadian subsidiary, Mylan Pharmaceuticals ULC, has received approval from Health Canada for Mylan-Bosentan tablets...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Dr. Reddy's Laboratories and Merck Serono, a division of Merck, Darmstadt, Germany, announced today a partnership to co-develop a portfolio of biosimilar compounds in oncology...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Dr. Reddy's Laboratories announced today that it has launched Ropinirole hydrochloride XR (extended-release) tablets...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Mylan today announced that its subsidiary Mylan Pharmaceuticals has resolved all disputes with Teva Pharmaceuticals USA. stemming from litigation brought by Mylan in federal court in the District of Columbia against the U.S. Food and Drug Administration (FDA) concerning Mylan's abbreviated new drug application (ANDA) for Modafinil tablets, 100 mg and 200 mg...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Perrigo today announced that it has agreed to settle its Hatch-Waxman litigation relating to Clobetasol propionate emulsion foam, 0.05% brought by Stiefel Research Australia, a GSK Company...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Astellas Pharma today announced that Astellas Pharma Europe ("Astellas Europe"), a European subsidiary of Astellas, launched Dificlir (generic name: Fidaxomicin) tablets, into the European market...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
In support of its commitment to maximise growth opportunities in China, Eli Lilly and Company today announced an increase of its network of manufacturing capabilities in this key emerging market country through an expanded collaboration with Novast Laboratories...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Abbott Laboratories settled patent lawsuits with generic-drug makers Watson Pharmaceuticals, Mylan and Lupin over its cholesterol drug Trilipix...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Breckenridge Pharmaceutical announced today that Breckenridge and Alembic Pharmaceuticals have settled their Paragraph IV patent litigation with Novartis concerning Rivastigmine tartrate capsules, a generic version of Exelon by Novartis, and that the U.S. Food and Drug Administration (FDA) approved their Abbreviated New Drug Application (ANDA)...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Merck known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey ruled against the company in a patent infringement suit against Apotex...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Watson Pharmaceuticals today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (Trospium chloride extended-release capsules) are invalid...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Pluristem Therapeutics announced today at the 2012 Bio International Convention the results of a pre clinical study it conducted measuring the effectiveness of its Placental eXpanded (PLX) cells when administered intramuscularly (IM)...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Pfizer Animal Health announces the availability of two new brands, Alverin Plus (Ivermectin/Clorsulon) and Flunixamine (Flunixin meglumine), providing additional animal health tools for producers and veterinarians...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Prodigy Health Supplier entered a Joint Venture with Stason Pharmaceuticals to bring a diverse line of quality generic pharmaceuticals to the U.S. market...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Medgenics, the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that its Infradure Biopump has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for the treatment of hepatitis D...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
All generic pharmaceutical companies, including Ranbaxy Laboratories, Cipla, Dr Reddy's Laboratories, Lupin, Glenmark and Torrent Pharma, might soon have to pay a fee to the US drug regulator when they seek its permission to sell their products there...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Teva Pharmaceutical announced today the launch of Olanzapine and Fluoxetine capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the company's generic equivalent of Symbyax...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
We are pleased to announce the launch of Rivastigmine capsules for generic prescription...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Teva Pharmaceutical announced today the U.S. District Court for the Southern District of New York has found in favour of Teva in the company's patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz and Mylan Laboratories/Natco Pharmaceuticals regarding Teva's relapsing-remitting multiple sclerosis (RRMS) product, Copaxone...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Shire, the global specialty biopharmaceutical company, announces that on June 22, 2012, the US Food and Drug Administration (FDA) responded to Shire's Adderall XR citizen petition...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Watson Pharmaceuticals today confirmed that its subsidiary, Watson Laboratories - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Desvenlafaxine succinate extended-release tablets, 50 mg and 100 mg...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Mylan today commented on an unfavorable ruling issued by the U.S. District Court for the Southern District of New York in relation to Teva's patent infringement lawsuit against Mylan in relation to Mylan's proposed generic version of Copaxone...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Dextroamphetamine saccharate, Amphetamine aspartate monohydrate, Dextroamphetamine sulfate, Amphetamine sulfate extended-release capsules CII...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Impax Laboratories and TOLMAR today announced that they will collaborate on a multiproduct agreement for the development, supply and distribution of generic topical prescription drug products...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Clindamycin phosphate and Benzoyl peroxide 1.2% / 5% topical gel, the generic equivalent of Duac gel...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
We are pleased to announce the launch of generic Ibandronic acid 150 mg film-coated tablets....
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
OxyContin is set to go off patent next year, but the maker of the powerful and heavily abused prescription painkiller is trying to extend its exclusive rights to the drug, arguing that a new version it spent $100 million to develop might substantially curtail abuse...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Breckenridge Pharmaceutical announced today that Breckenridge and Alembic Pharmaceuticals Limited were named codefendants in a Paragraph IV lawsuit filed by Pfizer concerning their ANDA Desvenlafaxine succinate extended-release tablets...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Drug firm Sandoz has filed a petition with the USFDA asking the health regulator to withdraw 180-days marketing exclusivity granted to Ranbaxy Laboratories for a generic version of Nexium, a drug used to treat stomach ulcer...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Mylan today announced that its Mylan Institutional business has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for preservative-free Thiamine hydrochloride injection, 100 mg/mL, packaged in 200 mg/2 mL multiple-dose vials...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Mylan today confirmed that the company has been sued by Pfizer, Wyeth, Wyeth Pharmaceuticals, and PF Prism in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Desvenlafaxine succinate extended-release tablets, 50 mg and 100 mg...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
Noven Pharmaceuticals today provided an update on the status of its pending Abbreviated New Drug Application (ANDA) seeking approval to market a Lidocaine topical patch 5%...
|
| |
|
|
Read more >>
|
| |
|
|
|
| |
|
European Union leaders cleared the final hurdle to an agreement on a common patent system, paving the way for improved and cheaper enforcement of intellectual-property rights...
|
| |
|
|
Read more >>
|
| |
|
|
|
|
|
Contribute
If you would like to contribute or publish your
company press releases at GenericsWeb, please
email us.
|
Home
